Nluc Reporter Cell Line - A20

The A20 cell line is a widely used murine B lymphocyte cell line derived from a spontaneous B-cell lymphoma in an aged BALB/c mouse. Established in the late 1970s, the A20 cell line exhibits characteristics of mature B lymphocytes, including surface expression of MHC class II molecules and Fc receptors. They are highly proliferative and easily cultured in vitro. A20 cells are particularly known for their ability to present antigens and activate T cells, making them a powerful tool for studying B cell biology, immune tolerance, antibody production, and autoimmune diseases. Their stability and reproducibility have made them important in research on immune responses, cancer immunotherapy, and signaling pathways such as NF-κB activation.

The Nluc reporter gene cell line - A20 is genetically engineered to express NanoLuc luciferase (Nluc), a novel bioluminescent enzyme with high sensitivity and a broad dynamic range. This modification enables real-time quantitative monitoring of cellular processes with exceptional precision. Applications include high-throughput screening of therapies targeting B-cell malignancies, tracking tumor growth in vivo using bioluminescent imaging, and evaluating drug efficacy in preclinical models. Researchers utilize this cell line to study immune checkpoint inhibitors, cytokine signaling, and apoptotic pathways by fusing Nluc to specific promoters or response elements. Its low background signal and high signal-to-noise ratio facilitate the rapid detection of subtle changes in gene expression, protein interactions, or cell viability, thereby accelerating drug discovery and mechanistic research in oncology and immunology.